PubMed Health⌕ Search

PubMed · 47824

Immunity to influenza.

Abstract

Immunity to influenza virus may be considered from the standpoints of viral and hostfactors. Amonst viral factors the phenomena of antigenic 'shift' and 'drift' of the surface antigens. Hemagglutinin HA and neuraminidase NA, are of utmost importance in enabling the virus to combat host immunity and to produce recurrent pandemics and epidemics of disease. 'Shift' involves major changes in the antigenic character of the HA and NA antigens, and serological studies reveal little or no crossreactions between antigens of different subtypes. However, immunological 'memory' may exist between the surface antigens of viruses of different subtypes, for example between the hemagglutinins of Asian (H2) and Hong Kong (H3) subtypes. Antigenic 'drift' occurs more frequently than 'shift' and involves subtle changes in the antigenic configuration of HA and NA within a subtype. It is clear that the hemagglutinin antigen contains a multiplicity of antigenic determinants, one or more of which remain stable (CR determinants) whilst others (strain-specific determinants) change completely during antigenic 'drift'. Amongst host factors humoral antibody to HA and NA appears to be a reasonable index of natural or vaccine induced immunity to infection. As far as the specificity of such antibodies is concerned, it is likely that future studies will place considerable emphasis on the distinction between antibody for the stable (CR) antigenic determinants and antibody to strain-specific determinants. It seems likely that antibody to strain-specific determinants is of more relevance to immunity than CR antibody. The studies of Virelizier et al. described elsewhere in this Symposium employing single-radial-diffusion tests give hope of simple methods for the investigation of such antibody specificity. There is no evidence that antibody to the internal, antigenically stable ribonucleoprotein is related to immunitywhilst the role of the other internal antigen, the membrane protein, in immunity is at present unknown. Numerous studies have been carried out to establish the importance of secretory antibody in the respiratory tract. Although secretory IgA specific for the influenza virus has been clearly demonstrated in the respiratory tract, the levels are low and its significance is not yet established. Whilst the role of cellular aspects of immunity to influenza in man remains to be established there is no doubt from the recent studies of Tyrrell and his colleagues that delayed hypersensitivity to influenza antigens can be demonstrated. In considering the host aspects of immunity it is important to attempt to distinguish factors which are merely an index of past exposure and those which are involved with the actual mechanism of immunity. It is likely that animal experimental models, in particular with inbred mice, will provide an important contribution in this field of investigation.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G C Schild, J S Oxford, J L Virelizier. 1975. Immunity to influenza.. https://pubmed.ncbi.nlm.nih.gov/47824/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Recombinant protein-based assays for detection of antibodies to severe acute respiratory syndrome coronavirus spike and nucleocapsid proteins.

Recombinant severe acute respiratory syndrome (SARS) nucleocapsid and spike protein-based immunoglobulin G immunoassays were developed and evaluated. Our assays demonstrated high sensitivity and specificity to the SARS coronavirus in sera collected from patients as late as 2 years postonset of symptoms. These assays will be useful not only for routine SARS coronavirus diagnostics but also for epidemiological and antibody kinetic studies.

Antibodies, Viral↗

"There is such a thing as asking for trouble": taking rapid HIV testing to gay venues is fraught with challenges.

OBJECTIVES: To explore the feasibility and acceptability of offering rapid HIV testing to men who have sex with men in gay social venues. METHODS: Qualitative study with in-depth interviews and focus group discussions. Interview transcripts were analysed for recurrent themes. 24 respondents participated in the study. Six gay venue owners, four gay service users and one service provider took part in in-depth interviews. Focus groups were conducted with eight members of a rapid HIV testing clinic staff and five positive gay men. RESULTS: Respondents had strong concerns about confidentiality and privacy, and many felt that HIV testing was "too serious" an event to be undertaken in social venues. Many also voiced concerns about issues relating to post-test support and behaviour, and clinical standards. Venue owners also discussed the potential negative impact of HIV testing on social venues. CONCLUSION: There are currently substantial barriers to offering rapid HIV tests to men who have sex with men in social venues. Further work to enhance acceptability must consider ways of increasing the confidentiality and professionalism of testing services, designing appropriate pre-discussion and post-discussion protocols, evaluating different models of service delivery, and considering their cost-effectiveness in relation to existing services.

Antibodies, Viral↗

Biological feasibility of developing prophylactic vaccines for viral pathogens: incubation period as a critical parameter.

Vaccines for sixteen major human viral pathogens have been approved for use in humans. For most other major human viral pathogens, the absence of an efficacious prophylactic vaccine is not for lack of effort. To identify the key parameters of biologic feasibility that determine "certainty-of-success" for developing prophylactic vaccines for major human viral pathogens, basic characteristics of viruses, such as primary genomic structure, route of transmission, and durability of viral infection were reviewed. These basic characteristics of viruses simply do not associate with successful vaccine development, so one must look elsewhere for characteristics predictive of successful vaccine development. Herein existing data are put forth in a way that demonstrates the impact of the combined effect of incubation period and broadly protective, relative immunogenicity on the "certainty-of-success" of developing effective vaccines for thirty viral pathogens. Both incubation period and broadly protective, relative immunogenicity appear to have accounted for much of the past successes in vaccine development, and may be useful in predicting where near term successes are most apt to occur.

Antibodies, Viral↗